West Pharmaceutical Services, Inc. — Q1 2021 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three months ended March 31, 2021, compared with the same period in 2020. West manufactures containment, packaging, drug-delivery and contract-manufactured products for biologic, generic, pharmaceutical, diagnostic and medical-device customers. Reportable segments are Proprietary Products and Contract-Manufactured Products.
Manufacturing operations continued during the COVID-19 pandemic, with enhanced safety measures and higher production at certain facilities to meet customer demand. Approximately $102.9 million of Proprietary Products sales related to COVID-19 activity, including vaccines, antiviral treatments and treatment of COVID-19 symptoms.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Net sales | $670.7 million | $491.5 million |
| Gross profit / margin | $271.9 million / 40.5% | $167.0 million / 34.0% |
| Operating profit / margin | $175.6 million / 26.2% | $88.0 million / 17.9% |
| Adjusted operating profit / margin | $179.2 million / 26.7% | $88.0 million / 17.9% |
| Net income | $151.2 million | $74.3 million |
| Diluted EPS | $1.99 | $0.99 |
| Operating cash flow | $88.7 million | $57.1 million |
Revenue increased 36.5% year over year, including a favorable $26.5 million foreign-currency translation impact; organic growth excluding currency was 31.1%. Proprietary Products sales rose 45.6% as reported, or 39.6% organically, while Contract-Manufactured Products sales rose 7.6% as reported, or 4.0% organically.
SG&A increased 11.7% to $80.2 million, but declined to 12.0% of sales from 14.6%. R&D increased 14.0% to $12.2 million. The effective tax rate was 16.4%, compared with 17.4%, partly reflecting $11.1 million of tax benefits from stock-based compensation.
Cash, debt and liquidity
- Cash and cash equivalents were $483.7 million at March 31, 2021, down from $615.5 million at December 31, 2020.
- Debt was $254.6 million, including $252.3 million of long-term debt. The $300 million revolving credit facility had no borrowings and $297.5 million of available capacity, including outstanding letters of credit.
- Working capital was $844.2 million, compared with $870.3 million at year-end 2020.
- Capital expenditures were $54.7 million, compared with $32.1 million in Q1 2020.
- Financing cash outflows were $156.4 million, including $137.1 million for repurchases of 479,000 shares and $12.6 million of dividends.
- Management stated that cash on hand, operating cash flow and available credit should meet foreseeable liquidity needs. The company was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Gross profit increased 62.8%, with the margin expanding 6.5 percentage points, driven by favorable product mix, $11.8 million of fees from certain cancelled COVID-19 supply agreements, pricing and production efficiencies.
- Operating profit increased 99.5%, primarily due to higher Proprietary Products sales and margins, including COVID-19-related demand.
- Net income and diluted EPS approximately doubled year over year.
- Operating cash flow increased by $31.6 million, while capital spending increased by $22.6 million and financing cash use increased by $36.1 million, primarily because of higher share repurchases.
- Other expense was $3.9 million versus other income of $3.5 million in Q1 2020. Q1 2021 included $1.2 million of restructuring charges, a $2.2 million cost-investment impairment and a $0.7 million SmartDose contingent-consideration charge.
- Foreign currency translation produced a $28.4 million other comprehensive loss, compared with a $47.3 million loss in Q1 2020.
Guidance, outlook, commentary and risks
The filing does not provide specific full-year revenue or earnings guidance. Management described liquidity and capital resources as strong and expects operations, capital expenditures and scheduled debt payments to be adequately funded. A July 2020 restructuring plan is expected to generate approximately $15 million to $17 million of total charges over up to 24 months; $5.8 million had been recorded through March 31, 2021.
Key uncertainties include the duration and effects of COVID-19, customer demand and inventory changes, supply-chain interruptions, availability and cost of labor and raw materials, petroleum-based input costs, foreign-exchange movements, regulatory approval and commercialization of customer products, competition, reliance on certain suppliers and affiliates, and the sustainability of elevated high-value and COVID-19-related demand.
The Vial2Bag product line, recalled in 2019 because of potential variable dosing, returned to the market after FDA clearance of the Vial2BagAdvanced 20mm Admixture Device in October 2020. The company reported no material changes to previously disclosed legal proceedings, commitments, contingencies or risk factors.
Investor verification points
- Determine how much of the Q1 growth and margin expansion is recurring versus attributable to COVID-19 demand and the $11.8 million of cancelled-supply-agreement fees.
- Monitor customer demand, order patterns and potential normalization of biologics and vaccine-related activity.
- Reconcile GAAP operating profit of $175.6 million with adjusted operating profit of $179.2 million and review the treatment of restructuring, impairment, pension and amortization items.
- Assess the cash impact of continued share repurchases, capital expenditures and the scheduled debt maturity, including the Series A notes due July 2022.
- Review exposure to supply-chain constraints, petroleum-based raw-material costs, foreign currency and key suppliers or affiliates.
- Track the remaining $152 million authorization under the 2021 share-repurchase program and the company’s ability to maintain current margins as demand mix changes.